November 12, 2019 — Lunit, a leading medical AI software company devoted to providing AI-powered total cancer care, will be returning to the 105th Radiological Society of North America (RSNA) this year with the latest, up-to-date AI solutions for chest and breast radiology. The state-of-the-art software—Lunit INSIGHT CXR 3 and Lunit INSIGHT MMG—will be available for demonstration at the Lunit booth located on AI Showcase floor, #10732.
During RSNA 2019, Lunit will present key clinical study results conducted to validate the specific clinical utility of its products, along with other abstracts that study AI-driven mammography & DBT, and AI-based detection of chest abnormalities such as pneumothorax and tuberculosis. Lunit is one of the few companies in the industry that highlights evidence-based studies and publications.
Lunit INSIGHT CXR and Lunit INSIGHT MMG, Lunit's most mature products tested on more than 3 million images from over 80 countries combined, will also be presented for demo. These software products, now installed and in use at hospitals and other medical institutions around Mexico, UAE, China and South Korea, has been receiving positive comments and feedback from its users, especially for its accuracy at 97-99 percent in the detection of lung abnormalities and breast cancer, signaling a successful takeoff for commercialization.
On Tuesday, Dec. 3 at 10:30 a.m., Brandon Suh, CEO of Lunit, will be on stage at AI Theater to give a presentation about the most recent activities and product developments of the company. Titled, “AI-powered Precision Diagnostics - Beyond Expert Level Imaging Biomarkers for Chest and Breast Imaging,” Suh will present how Lunit expands the boundaries of AI-driven medical image analysis and how Lunit’s AI solutions present a new paradigm of AI-assisted radiology workflow.
For more information: www.lunit.io
May 27, 2026 
